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Primary Angioplasty Is Cost-Minimizing
ompared With Pre-Hospital
hrombolysis for Patients Within 60 Min
f a Percutaneous Coronary Intervention Center
he Comparison of Angioplasty and Pre-Hospital Thrombolysis
n Acute Myocardial Infarction (CAPTIM) Cost-Efficacy Sub-Study
acques Machecourt, MD,* Eric Bonnefoy, MD,† Gérald Vanzetto, MD,* Pascal Motreff, MD,‡
téphanie Marlière, MD,* Alain Leizorovicz, MD, PHD,§ Benoit Allenet, PHD,
ean Michel Lacroute, MD,¶ Jean Cassagnes, MD,‡ Paul Touboul, MD†
renoble, Lyon, and Clermont Ferrand, France
OBJECTIVES This ancillary study of the Comparison of Angioplasty and Pre-hospital Thrombolysis in
Acute Myocardial Infarction (CAPTIM) trial sought to assess the cost-efficacy ratio of
primary coronary angioplasty (PCA) and pre-hospital thrombolysis (PHT) in patients
suffering from an acute myocardial infarction (AMI) (6 h) close to (60 min journey) a
percutaneous coronary intervention (PCI) center.
BACKGROUND In the CAPTIM study, at 30 days follow-up PCA was as equally effective as PHT with rescue
angioplasty if needed. The cost efficacy of these two strategies has not yet been compared.
METHODS Data were prospectively collected for 299 patients in three centers. The efficacy analysis was
extended at one-year follow-up for those patients. Direct fixed and variable actual costs were
assessed with a piggyback data collection.
RESULTS The one-year primary end point event-rate (death, non-fatal myocardial infarction, and
stroke) was not different after PCA or PHT (14% vs. 16. 4%, p  NS). Costs were lower in
the PCA group either during the in-hospital period (8,287 vs. 9,170 $, p  0.0001) and after
one-year follow-up, in relation to a higher rate of subsequent revascularizations in the PHT
group (49% vs. 23%, p  0. 01), leading to a longer hospital stay (10 vs. 9.1 days, p  0. 03).
CONCLUSIONS After AMI in patients less than 1 h from a PCI center, PCA is as effective and less costly than
a combined strategy of PHT followed by rescue angioplasty. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.031515–24) © 2005 by the American College of Cardiology Foundation
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ihe aim of reperfusion therapy in acute myocardial infarc-
ion (AMI) is to achieve complete and sustained patency of
he infarct-related coronary artery as soon as possible. When
atients are located more than a 60- to 90-min journey from
catheterization facility, thrombolysis is recommended as
he first-line approach (1,2). In comparison to in-hospital
dministration, pre-hospital thrombolysis (PHT) is partic-
larly useful in such patients as it is associated with an
verage gain of 60 min or more in some situations, resulting
n a 17% reduction in death rate (3,4). For patients within
90-min journey of a percutaneous coronary intervention
PCI) center, data are more controversial: primary coronary
ngioplasty (PCA) rather than in-hospital thrombolysis is
ften advocated as a higher reperfusion rate is obtained with
ngioplasty without an excessive delay in reperfusion. Con-
equently the mortality rate is lower (5) even in patients who
From *Coronary Care Unit and Pharmacy Department, CHU Grenoble,
renoble, France; †Coronary Care Unit, Hopital Louis Pradel, Lyon, France;
Coronary Care Unit, Centre Hospitalo Universitaire Clermont Ferrand, Clermont
errand, France; §Clinical Pharmacology Unit, Laennec University, Lyon, France;
nd ¶Service d’Aide Médicale Urgente (SAMU) 38, Grenoble, France. The
APTIM trial was supported by public funding (Programme Hospitalier de Recher-
he Clinique, from the French Ministry of Health).(
Manuscript received May 10, 2004; revised manuscript received October 30, 2004,
ccepted November 2, 2004.ave to be transferred from a community hospital to a PCI
enter (6–8). However, when PHT is available, the choice
f optimal reperfusion therapy remains more difficult, as a
aster reperfusion obtained by this technique is being bal-
nced against a higher reperfusion rate obtained with
rimary angioplasty. The main result of the recent Com-
arison of Angioplasty and Pre-hospital Thrombolysis in
cute Myocardial Infarction (CAPTIM) study comparing
CA and PHT with rescue angioplasty if needed is that
oth strategies lead to equivalent results in terms of major
vents at 30-day follow-up (9).
Little data is available assessing the cost-efficacy of
rimary angioplasty versus in-hospital thrombolysis
10–13), and no study to our knowledge has compared
HT with primary angioplasty in patients presenting
ith AMI. The cost-efficacy analysis of the CAPTIM
tudy was planned to prospectively collect data concern-
ng efficacy and costs during the initial hospitalization
eriod, and at one-year follow-up in every patient in-
luded by three university hospitals participating in the
APTIM study. This ancillary study aimed to determine
hether one of these two reperfusion strategies is dom-
nant (more effective and cost-saving), cost-effective
more effective with a moderate incremental cost), or
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The CAPTIM Cost-Efficacy Sub-Study February 15, 2005:515–24ost-minimizing (both strategies are equally effective but
ne is cost-saving).
ETHODS
tudy design. The methodology of the CAPTIM study
as been previously described (9). Patients within 6 h from
nset of a ST-segment elevation AMI were randomly
ssigned at the site of initial management by the mobile
mergency care unit (Service d’Aide Médicale Urgente
SAMU]) to PHT with intravenous infusion of alteplase or
CA. Patients were excluded if the duration of transfer to
he PCI center was expected to exceed 1 h, that is, if first
are-to-balloon time was more than 90 min. Patients with
ardiogenic shock, or any other contraindication to throm-
olysis at presentation were also excluded.
For the cost-efficacy sub-study, 299 patients from the
hree participating centers were consecutively enrolled be-
ween June 1997 and September 2000; of these, 289
ompleted follow-up. Ten patients were lost to follow-up
fter the initial hospitalization period, as they had moved to
nother area (six in the PCA group, five in the PHT group).
one had presented with a Killip class2 or experienced an
nd point during the initial hospitalization. Mean age and
Abbreviations and Acronyms
AMI  acute myocardial infarction
CAPTIM  Comparison of Angioplasty and
Pre-hospital Thrombolysis in Acute
Myocardial Infarction
PCA  primary coronary angioplasty
PCI  percutaneous coronary intervention
PHT  pre-hospital thrombolysis
PTCA  percutaneous transluminal coronary
angioplasty
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Baseline Characteristics
Parameters
Cost-Efficacy A
PCA (n  149) P
Age (yrs) 59.4  12
Male 115 (77.1)
Current smokers 62 (58.4)
Diabetes 25 (16.7)
Dyslipidemia 88 (59.1)
Previous MI 23 (15.4)
Anterior infarction 79 (46.9)
Heart rate at admission
(beats/min)*
75 [64–89]
Systolic blood (mm Hg)* 130 [115–143] 1
TIMI risk score* 2 [1–4]
Killip 4 at admission 3 (2.1)
Killip 4 in-hospital 8 (5.6)
Time to treatment (min) 184 [153–261] 1
Results are number (%) except as otherwise indicated. *Medi
cost-efficacy analysis. ‡Student test p  0.001 and §student
CAPTIM  Comparison of Angioplasty and Pre-hospita
infarction; PCA  primary coronary angioplasty; PHT  pre-ho
Infarction.uration of hospitalization were not different from the
hole group. Baseline characteristics and clinical presenta-
ion of the patients included in the cost-efficacy analysis
ere not different from those of the whole CAPTIM
opulation. There was no difference between patients as-
igned to PHT and those assigned to primary angioplasty
Table 1). However, patients in the cost-efficacy study were
on-significantly older (59.5 vs. 58 years) and presented
ore often with diabetes mellitus (14.3% vs. 12.6%, p 
.05). Consistent with the results of the main study,
ardiogenic shock occurring between first care and admis-
ion to the PCI center or to the intensive care unit was more
ften present in the primary angioplasty arm. The ethics
ommittee of one of the three hospitals approved this study,
nd all eligible patients provided a written informed consent.
The analysis was performed from a societal perspective
ith a time horizon of one year. The primary clinical end
oint for efficacy as defined in the CAPTIM study was a
omposite of death, non-fatal re-infarction, and non-fatal
isabling stroke within 30 days and was extended to
ne-year follow-up. The secondary clinical end point ex-
ended the efficacy definition to end points that included
mergent or delayed revascularization (angioplasty or coro-
ary artery bypass graft surgery) and frequency of severe
leeding. All events were assessed up to 120 min after
ospital admission, at discharge, and after one-year follow-
p. Immediate angioplasty was defined as any revascular-
zation performed at the patient’s admission (primary an-
ioplasty for patients included in the PCA group and rescue
ngioplasty for patients included in the PHT group); rescue
ngioplasty was performed if suitable for any patients with
o clear clinical evidence of reperfusion (persisting chest
ain and/or significant ST-segment elevation) 60 to 120
in after the bolus injection of alteplase. Emergent angio-
lasty was defined as any revascularization (except primary
sis Whole CAPTIM Study
n  150) PCA (n  421) PHT (n  419)
 12 58  11 58  10
(83.3) 343 (81.5) 345 (82.5)
(54.7) 205 (49.2) 216 (52.6)
(12) 57 (13.5) 46 (11.1)
(60) 215 (51.4) 212 (51.1)
(21.3) 51 (12) 56 (13)
(46) 178 (42.7) 166 (40.2)
9–88] 75 [66–88] 75 [64–84]
15–140] 128 [111–140] 125 [110–140]
–4] 2 [1–4] 2 [1–4]
0† 9 (2.1) 0‡
(2.7) 20 (4.9) 10 (2.5)§
7–176] 190 [149–255] 130 [95–180]
erquartile range]. †Student test p  0.07 versus PCA in the
 0.09 versus PCA in the whole CAPTIM study.
mbolysis in Acute Myocardial Infarction; MI  myocardialnaly
HT (
59.5
125
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February 15, 2005:515–24 The CAPTIM Cost-Efficacy Sub-Studyr rescue angioplasty) performed during the initial hospi-
alization period. Emergent angioplasty was driven by the
ccurrence of ischemia (chest pain or electrocardiographic
hanges) or performed at the discretion of the investigator
elective angioplasty). Elective angioplasty was encouraged
hen the PCI of the infarct-related artery was Thrombol-
sis In Myocardial Infarction (TIMI) flow grade 0, 1, or 2,
r when ischemia has been shown on non-invasive tests but
ngioplasty of a non-infarct-related artery was not recom-
ended. Delayed revascularization was defined as the need
or revascularization owing to recurrent ischemia from the
nd of the initial hospitalization period up to one year.
ecurrent infarction and post-angioplasty infarction were
efined as recurrent chest pain with a new ST-segment
levation and an associated increase in creatine kinase and
reatine kinase-MB fraction. Creatine kinase, creatine
inase-MB fraction, and troponins were measured every 6 h
he first day and at least once a day during the following
ays, and routinely 6 to 12 h after an angioplasty. Computed
omographic or magnetic resonance imaging brain scans
ere requested for all patients suspected of stroke. Severe
leeding was defined as any intracranial hemorrhage or any
leeding that required blood transfusion. A clinical events
ommittee adjudicated all events.
ources of cost data. Resource use was identified using a
iggyback data collection. Only direct costs (fixed and
ariable) were considered. Initial hospitalization and one-
ear costs were assessed. An ancillary micro-costing study
as developed in two of the three hospitals (211 of 299
atients); the unit cost of each procedure was extended to
he third hospital. The current cost estimation was per-
ormed in the clinical pharmacy unit of the Grenoble
niversity hospital. Valuation of resources for services and
rocedures was performed from actual costs derived from
he accounting data system of the hospital, and for drugs
nd devices on market prices. All costs are expressed in U.S.
ollars using the 2000 exchange rate for the French franc. A
% discounting rate was applied.
Costs of pre-hospital care by the mobile emergency-care
nit were calculated according to the duration of the
ntervention and the duration of helicopter flight if needed.
osts of hospitalization were assessed in the cardiology
ntensive care unit, in the general ward, and in the surgical
ntensive care unit. The mean cost for one day spent in these
ifferent units was obtained by adding fixed costs (facilities,
quipment, maintenance) variable costs (generic caregiver
ime, catering, supplies except drugs, laboratory tests, and
nterventions). Labor costs for physicians, nurses, or tech-
icians were derived from overall number of hours worked
er year during normal working hours, weekends, or nights
ultiplied by the hourly rate of salary divided by the number
f patient-days that year.
Concerning revascularization procedures, we first evalu-
ted the basal cost of coronary angiography and percutane-
us transluminal coronary angioplasty (PTCA) (which in-
luded physicians and nurses charges, the cost of tisposables, the cost of contrast agent, and the depreciation
f the catheterization laboratory equipment), and subse-
uently, the cost of single-use treatments (stents, balloons,
lycoprotein IIb/IIIa receptor antagonists, intra-aortic bal-
oon pump) needed for each patient was added. The cost of
oronary bypass was calculated in the same way.
Concerning drugs, the unit price for the thrombolytic
gent was added to the price of the other cardiac (aspirin,
lopidogrel, heparin, beta-blockers, angiotensin-converting
nzymes) or non-cardiac (statins, anti-diabetic drugs) treat-
ents. We also estimated a median cost per day for all
edical examinations, including standard biologic tests,
lectrocardiography, and pulmonary radiography. The num-
er of echocardiographies, exercise stress tests, and nuclear
ardiology studies were assessed for each patient during the
n-hospital period and then up to one year.
To determine whether our results can be extended to
ther health care systems, a sensitivity analysis was per-
ormed: U.S. and U.K. unit costs were estimated by apply-
ng U.S. and U.K. unit costs to resources used for our
atients. For the U.K., National Health and social care
eference costs were taken. Hospitalization and revascular-
zation procedure costs (PCI, coronary artery bypass graft
urgery) were assigned on the basis of previous studies (14).
he costs of drugs were obtained from the British National
ormulary. Accordingly, for the U.S. costs, hospitalization
osts in the coronary care unit, normal ward, revasculariza-
ion procedure costs, and drug costs were derived from
revious studies (15–17). In these studies involving a large
umber of centers, the charges were obtained from the
B92 Medicare Uniform Bill, and reduced to costs using
he Medicare cost to charge ratio of these centers. Physician
ees were assessed using the Medicare Fee Schedule (North
arolina version), taking into account the daily follow-up of
he patients, cardiac catheterization, and revascularizations
f the patients. Patient rehabilitation and pre-hospital
ransportation costs were assessed using the Medicare ref-
rence coverage.
tatistical analysis. All analyses were performed on the
asis of the intention-to-treat principle. For the CAPTIM
tudy, a sample of 1,200 patients was chosen to ensure the
etection of an absolute reduction of 5% of the primary end
oint in one group; for the cost-efficacy study, 300 patients
ere chosen to enable the detection of a 10% absolute
eduction of the in-hospital total cost between the groups
ith an alpha error of 0.05 and a beta error of 0.15. As
nally only 289 patients have been studied, a post hoc
nalysis of the statistical power of the study was performed:
ith the same hypotheses for standard deviation, a differ-
nce of 10.25% for the in-hospital cost between the two
roups was needed in order to be detected.
Discrete data are reported as number (frequencies) and
ontinuous data as mean  SD. Costs are reported as mean
SD and [median] values. Normally distributed continu-
us variables (as assessed by graphic comparison to the
heoretical normal function of same mean and standard
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The CAPTIM Cost-Efficacy Sub-Study February 15, 2005:515–24eviation) were compared by Student t test and discrete data
y a chi-square test. Costs and non-normally distributed
ata were compared using a Mann-Whitney non-
arametric test. Analyses were performed in some sub-
roups of patients, related to the initial clinical presentation
age, gender, Killip class, TIMI risk score, location of the
MI), the occurrence of the primary end point, and the
eed of an immediate or an emergent angioplasty. The
tatistical power for these subgroup analyses was calculated
aking into account the number of comparisons performed.
he cost-efficacy ratio of the two strategies was assessed; the
ost difference between PHT and PCA was compared with
he difference in efficacy (in terms of primary and secondary
linical end points as previously defined).
ESULTS
rimary and secondary clinical end points. The occur-
ence of a 30-day primary clinical end point was not
ifferent for PCA and PHT (7.7% vs. 12.3%, p  NS).
here was also no difference after one-year follow-up (14%
s. 16.4%, pNS). The trend towards a better outcome for
he primary angioplasty group was driven by a decrease in
he 30-day re-infarction rate (1.4% vs. 5.5% for PHT, p 
.11). During the in-hospital period, major bleeding oc-
urred in five patients in the PCA group (groin hematoma
ith significant deglobulinization) versus none in the PHT
able 2. Hospital Stay and Frequency of Cardiac Revascularizatio
Initial Hospi
PCA
(n  143)
PH
(n 
ospitalizations
ICCU (days) 3.4 [3] 3.7 [
Medical ward (days) 5.7 [5] 6.3 [
Other ICU (days) 0.4 [0] 0.5 [
Total in-hospital stay (days) 9.5 [9] 10.5 [
Cumulative re-hospitalization (days) — —
Rehabilitation (days) — —
evascularizations procedures
(number of patients)
†
Coronary angiographies 140 (98) 121 (8
Immediate PCI (primary or rescue) 126 (88) 51 (3
Emergent PCI 14 (10) 61 (4
PCI total 129 (90) 90 (6
Stent 103 (72) 74 (5
GP IIb/IIIa inhibitors 43 (30) 5 (3
Thrombolysis 7 (5) 146 (1
Intra-aortic balloon pump 11 (8) 6 (4
CABG 1 (0.7) 0
esting
Exercise stress tests 77 (54) 67 (4
Nuclear cardiology studies 34 (24) 45 (3
Echocardiography 110 (77) 118 (8
ata are numbers (%) except as otherwise indicated. Days of hospitalization are me
CABG  coronary artery bypass graft surgery; GP  glycoprotein; ICCU  inte
CI  percutaneous coronary intervention; PHT  pre-hospital thrombolysis.roup. The secondary clinical end point (primary clinical mnd point  major bleeding  revascularizations) after one
ear was significantly lower in the PCA group than in the
HT group (34% vs. 61%, p  0.0001).
echanical revascularization (Table 2). During the in-
ospital period, in the PCA group all patients except three
nderwent an immediate coronary angiography as planned,
ollowed by immediate PCI in 88% of cases. Pre-procedure,
3% of these patients were TIMI flow grade 3 and 5% had
on-significant (30%) stenosis. Post-procedure, 84% of
atients were TIMI flow grade 3, 11% TIMI flow grade 2,
nd 5% TIMI flow grade 0 to 1. At the end of the initial
ospitalization period as well as after one-year follow-up,
he revascularization rate did not change significantly, 90%
f patients being revascularized (some patients had two
evascularizations or more). In the PHT group, 83% of the
atients required a coronary angiography during the initial
ospitalization period leading to 35% of patients with a
escue angioplasty, 62% of patients with a rescue or an
mergent angioplasty, and 68% of patients revascularized
fter one year. Emergent angioplasty was driven by recur-
ence of ischemia for 12% of patients and was elective in
8% of patients.
Consequently, fewer patients underwent a PCI after
HT than after PCA, but more patients underwent an
mergent or delayed PCI (49% vs. 23%, p  0.001).
evascularization by bypass surgery was performed in 5.6%
n the PCA group versus 6.4% in the PHT group (p  NS)
nd Testing
tion One-Year Follow-Up
p Value
PCA
(n  143)
PHT
(n  146)
p
Value*
0.03 3.7 [3] 4 [3.5] 0.03
0.05 8.1 [5] 9.2 [6] 0.03
NS 0.6 [0] 0.6 [0] NS
0.009 12.4 [9] 13.8 [10] 0.01
— 2.9 [0] 3.3 [0] NS
— 7.9 [0] 9.9 [0] NS
0.001 140 (98) 125 (86) 0.001
0.001 — — —
0.001 — — —
0.001 129 (90) 99 (68) 0.001
0.001 103 (72) 80 (55) 0.001
0.0001 43 (30) 5 (3.4) 0.0001
0.0001 7 (5) 146 (100) 0.0001
0.19 11 (8) 6 (4) 0.19
NS 8 (5.6) 10 (6.4) NS
†
0.04 108 (76) 106 (73) NS
0.07 57 (40) 65 (45) NS
NS 119 (83) 125 (86) NS
dian]. *Mann-Whitney p values. †Chi-square p values.
oronary care unit; ICU  intensive care unit; PCA  primary coronary angioplasty;ns a
taliza
T
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February 15, 2005:515–24 The CAPTIM Cost-Efficacy Sub-Studyosts analysis. Reference costs of all resources used are
hown in Table 3, left column. Mean costs of initial
ospitalization were $883 significantly lower in the PCA
roup than in the PHT group (11%, p  0.008). The
372 significantly higher cost of hospitalization in the PHT
roup was the result of a longer hospital stay, either in the
oronary care unit or in the general ward (Table 2). The
umber of re-hospitalization days was not different in the
wo groups. For the revascularization procedures, as ex-
ected, catheterization and angioplasty were more costly in
he PCA group compared with the PHT group. The mean
otal cost of angioplasty was $1,997 in the PCA group
including an average cost of $300 per patient for glyco-
rotein IIb/IIIa antagonist used in one-third of patients
efore or during angioplasty) versus $1,243 in the PHT
roup. On the other hand, the additional cost of the
hrombolytic agent in the PHT group more than offset the
igher cost of PCI in the PCA group, and revascularization
as $283 significantly more costly in the PHT group than
n the PCA group. Mobile care unit pre-hospital transpor-
ation was also more costly for the PHT patients because of
he preparation time of alteplase.
At one-year follow-up, costs remained $1,224 signifi-
antly lower in the PCA group than in the PHT group
p  0.04) with no further significant difference between
he end of the initial hospitalization period (accounting
or about 70% of the overall cost) and one year. Re-
ospitalization rate, costs of drugs, and fees for exercise
tress tests, echocardiography, or nuclear studies were not
ifferent between the two groups (Tables 2 and 3).
ensitivity analysis. Applying U.S. and U.K. costs to our
atients (Table 4), total average costs at the end of the initial
ospitalization were, respectively, 1.9 and 1.6 higher. Pre-
ospital care was the only cost remaining higher in our
tudy. Revascularization procedures (PTCA, coronary ar-
ery bypass graft surgery, and thrombolysis) were twice as
xpensive as in the U.S. or U.K. system. After one-year
ollow-up, figures were not different.
Concerning the cost comparison of the two groups of
atients, when applying U.K. and U.S. costs, PHT re-
ained more expensive than PCA, whether at the end of
he initial hospitalization (7.5% with U.K. costs, 9%
ith U.S. costs vs. 11% in our study) or at one-year
ollow-up (9% with U.K. costs, 10.5% with U.S. costs
s. 10% in our study).
ubsets analysis for cost comparison (Fig. 1). Results
ere not different whether based on gender, age, or
ocation of the AMI, PCA being less expensive than
HT. However, they were influenced by the presence of
linical risk factors at presentation (the Killip class, heart
ate, systolic blood pressure, alone or combined). Primary
oronary angioplasty was less costly than PHT only for
on-high-risk patients and there was no difference in cost
etween the two strategies for high-risk patients, these
atients being significantly more expensive than non-
igh risk patients whatever the treatment used. Similarly, (CA was less costly than PHT for patients free of a
rimary clinical end point, whereas no difference was seen
n patients who experienced at least one event, and PCA
as less costly than PHT whether or not an immediate or
mergent PCI was performed. However, the difference in
avor of PCA was particularly large for patients who did
ot need an immediate PCI ($2,000 saved) as the initial
oronary angiography selected low-risk patients, with an
arly discharge of these patients. The PHT patients who
id not need a rescue angioplasty were costlier than PHT
atients followed with rescue angioplasty (p  0.01), but
s costly as PCA patients. Results were not modified
sing U.S. or U.K. costs.
ost-efficacy ratio. At one-year follow-up when the pri-
ary clinical end point for efficacy is considered, PCA is a
ost-minimizing strategy with a non-significant difference
n efficacy but 10% less costly than PHT, and with the same
elative difference when applied to U.S. and U.K. costs.
hen the secondary clinical end point for efficacy is
onsidered (including further revascularizations), PCA was
oth significantly more effective and less costly than PHT
nd is consequently a dominant strategy in the population
tudied.
ISCUSSION
n ideal strategy is a treatment that can both improve
linical outcome and save costs and resource consumption.
oreover, it must be applicable to the majority of diseased
atients. Over the last 10 years, PCA has shown better
linical outcome and lower cost for several subsets of
atients than hospital thrombolysis in skilled high-volume
atheterization centers (5,6,12), whereas results from regis-
ries during the same period have been less favorable (11).
he CAPTIM study was designed to compare PHT (com-
ined with rescue angioplasty if needed) to PCA in patients
ithin a short distance of a catheterization center. A
entralized triage system allowed direct transportation of the
atient to the catheterization laboratory for the PCA arm or
o the cardiology intensive care unit for the PHT arm. The
ain result of the CAPTIM study indicates that the rate of
ajor cardiovascular events (death  re-infarction 
troke) is no different after PHT than after PCA. Moreover,
bout one-third of the patients treated by thrombolysis
eeded rescue angioplasty.
The CAPTIM cost-efficacy sub-study, performed pro-
pectively for all patients included in three of the partici-
ating centers, also shows a similar clinical outcome be-
ween the two strategies and highlights several important
ssues concerning resource consumption: the rate of imme-
iate mechanical revascularization was respectively 88% for
he PCA group and 35% for the PHT group (rescue
ngioplasty), whereas the rate of subsequent revasculariza-
ion was higher after PHT, either during the initial hospi-
alization period (42% vs. 10%) or after one-year follow-up
49% vs. 23%). Overall, less patients underwent revascular-
Table 3. Reference Costs of Resources and Costs Per Patient by Reperfusion Group
Reference
Cost ($)
In-Hospital Cost Per Patient One-Year Cumulative Cost Per Patient
PCA
(n  143)
PHT
(n  146)
Mann-Whitney
p Value
PCA
(n  143)
PHT
(n  146)
Mann-Whitney
p Value
Hospitalizations* Per day
ICCU 602 2,041  1,228 2,214  1,130 0.03 2,233  1,339 2,407  1,243 0.03
Other ICU 938 394  4,174 482  2,822 NS 490  4,325 588  3,018 NS
Medical ward 196 1,114  882 1,225  825 0.05 1,567  1,038 1,459  897 NS
Rehabilitation 201 1,595  3,138 2,038  5,749 NS
Subtotal 3,550  4,208 3,922  3,400 0.009 5,885  5,023 6,492  7,860 0.01
Revascularization procedures† Per unit
PCI procedure 971 1,037  370 752  469 0.001 1,246  798 873  632 0.0001
Balloon 180 38  88 17  61 0.02 48  102 18  66 0.02
Stent 679 603  463 428  498 0.0004 685  586 477  523 0.002
GP IIb/IIIa inhibitors (/unit) 990 298  455 34  180 0.0001 298  455 34  180 0.0001
Intra-aortic balloon pump 278 22  74 11  55 NS 22  74 11  55 NS
Overall PCI cost — 1,997  956 1,243  961 0.0001 2,299  1,472 1,413  1,118 0.0001
Overall CABG cost‡ 3,708 26  436 0 NS 199  854 244  940 NS
Thrombolysis (/unit) 1,117 54  241 1,117  0 0.0001 54  241 1,117  0 0.0001
Subtotal 2,077  939 2,360  961 0.006 2,552  1,449 2,774  1,118 0.04
Mobile care unit (/h) 866 1,036  378 1,239  434 0.003 1,036  378 1,239  434 0.003
Other medications (/day) 5 46  29 50  29 NS 675  311 746  368 NS
Testing and fees
Lab  X-ray  ECG (/day) 124 1,198  781 1,318  760 0.009 1,336  781 1,456  760 0.01
Echocardiography (/unit) 138 146  148 150  120 NS 219  250 225  234 NS
Nuclear cardiology 552 162  319 78  275 NS 281  413 291  384 NS
Exercise stress tests 93 72  79 53  63 0.02 148  132 133  114 NS
Subtotal 1,578  842 1,599  905 NS 1,984  961 2,105  950 NS
Total 8,287  5,160 9,170  4,323 0.0001 12,132  7,671 13,356  9,609 0.04
7,440 [6,236–8,719] 8,553 [7,181–9,490] 9,872 [8,483–14,689] 11,216 [8,816–14,555]
All costs are in U.S.$. *Fixed costs (facilities, equipment, maintenance)  variable costs (generic caregiver time, catering, supplies except drugs, laboratory tests, and interventions). †Caregiver time, contrast agents, sterile supplies,
maintenance (excluding stent and balloon costs). ‡Fixed costs (facilities, equipment, maintenance)  variable costs (labor costs, drugs, and supplies). Data are expressed as mean  SD or median [25–75 percentile].
ECG  electrocardiogram; GP  glycoprotein; PCA  primary coronary angioplasty; PHT  pre-hospital thrombolysis; other abbreviations as in Table 2.
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February 15, 2005:515–24 The CAPTIM Cost-Efficacy Sub-Studyzation in the PHT group after one-year follow-up (68% vs.
0% for the PCA group). Overall, direct costs were 11%
ignificantly lower at the end of the initial hospitalization
eriod after PCA and 10% lower after one-year follow-up.
he higher costs of mechanical revascularization in the
able 4. Sensitivity Cost Analysis Using U.K and U.S. Costs
U.K. Costs
PCI PHT
re-hospital 570 68
ospitalization 8,325 9,20
CI 3,628 2,47
ABG 43
hrombolysis/GP IIb/IIIa inhibitors 513 1,97
ther treatments 289 28
otal initial hospitalization 13,368 14,32
ehabilitation 2,488 3,11
e-hospitalizations 1,414 1,53
ew revascularizations 852 74
nitial to 1 yr 4,754 5,39
otal 1 yr 18,122 19,71
ll costs are in U.S. $. Hospitalization costs include cost in intensive coronary care u
adionuclide imaging, and professional fees. Outpatients’ follow-up costs are not inc
CABG  coronary artery bypass graft; GP  glycoprotein; PCI  percutaneous
igure 1. Subgroup analysis of difference of cost between pre-hospital th
aseline presentation, the presence of an immediate or emergent revascular
nfarction [MI], or stroke) or bleeding. White bars  PHT group; black bars 
nalysis was p  0.0086. SBP  systolic blood pressure.CA group, including physician and paramedic charges and
se of glycoprotein IIb/IIIa inhibitors, more than offset the
HT group by the cost of the fibrinolytic agent and the cost
ssociated with a longer hospital stay. This longer hospital
tay in the PHT group was the result of a higher rate of
U.S. Costs Present Study Costs
PCA PHT PCA PHT
700 820 1,036 1,239
10,069 11,129 5,128 5,521
4,476 3,083 1,699 1,209
103 0 26 0
512 2,242 352 1,151
360 370 46 50
16,220 17,644 8,287 9,170
2,804 3,515 1,594 2,038
3,169 3,525 740 532
1,417 1,419 475 414
7,390 8,459 2,809 2,982
23,610 26,103 11,096 12,152
d normal ward, laboratory and X-ray testing, echocardiography, electrocardiograms,
ary intervention; PHT  pre-hospital thrombolysis.
olysis (PHT) and primary coronary intervention (PCI), according to the
n, the occurrence of a major cardiac event (composite of death, myocardial2
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luded.romb
izatioPCI group. For a global risk alpha  5%, the significance level for each
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The CAPTIM Cost-Efficacy Sub-Study February 15, 2005:515–24e-infarction and a higher rate of recurrent ischemia as
ssessed by the recurrence of symptoms or stress tests,
eading to a higher rate of emergent angioplasties.
As to the efficacy criterion, the Primary Angioplasty in
yocardial Infarction (PAMI) study (18), the Global Use
f Strategies to Open Occluded Coronary Arteries
GUSTO) IIb substudy (19), the Air PAMI study (6), the
Rimary Angioplasty in patients transferred from General
ommunity hospitals to specialized PTCA Units with or
ithout Emergency thrombolysis (PRAGUE)-2 study (7),
he DANish Multicenter Randomized Study on Fibrino-
ytic Therapy versus Acute Coronary Angioplasty in Acute
yocardial Infarction (DANAMI-2) (8), and the Canadian
tenting versus Thrombolysis in Acute Myocardial Infarc-
ion Trial (STAT) (13) all demonstrated a better clinical
utcome with PCA. (All the studies used in-hospital
hrombolysis.) Our different results (same efficacy between
he two groups) can be explained by three factors: the
eneficial effect of the pre-hospital triage of our patients, the
re-hospital administration of the thrombolytic agent, and
he liberal use of rescue angioplasty after PHT. Pre-hospital
riage of the patients allows a very short time to reperfusion,
articularly for the PHT group (130 min), and more
atients were treated 2 h from the onset of pain, a
ituation where the fibrinolytic agents are more effective
20–22). Rescue angioplasty was performed in 35% of our
atients and in only 2% to 6% of patients in the other recent
tudies (7,8). The mortality rate in our PHT group is low
3.8%), and much higher in these studies (10.3% and 7.3%,
espectively).
Concerning resource consumption, most previous studies
ound that primary angioplasty was less costly than hospital
hrombolysis (6,10,12,13), and our study extends the result
o PHT. As in the present study, the PAMI sub-study also
ound lower costs for primary angioplasty, because of earlier
atient discharge and lower recurrence of ischemia (12).
he Canadian STAT study shows higher costs in the tissue
lasminogen activator group compared with the angioplasty
nes, this resulting from a longer hospital stay (13). De Boer
t al. (10) found no difference in costs but a better clinical
utcome after angioplasty. However, streptokinase, which is
ess expensive and less effective than alteplase. was used for
his study. Total costs reported in most studies for treatment
f acute coronary syndromes were higher than in the
APTIM study (10,12,14–17), and in a few studies (13)
otal costs and unit costs were close to our results. Total
osts in Stent-PAMI were $15,004 for PTCA without stent
mplantation versus $16,959 for PTCA with stent implan-
ation (23); in the Treat Angina with Aggrastat and
etermine Cost of Therapy with an Invasive or Conserva-
ive Strategy (TACTICS) study, total costs were $15,714
or the invasive approach versus $14,047 for the conservative
ne compared with $8,287 and $9,170 in CAPTIM and
6,354 and $7,893 in the STAT study. These differences in
otal costs may be explained by different factors: As noticed
y Taira et al. (24), the method used in cost estimates can lead to significant differences in results. The methods using
ospital charges converted to costs that are applied in most
tudies (10,12,14–17) lead to higher figures than the
bottom-up” method that used itemized costs from the local
ospital accounting system (13,23).
Differences in health care systems may be another impor-
ant factor. For instance, the median costs of drugs were
ery low in CAPTIM as statins, beta-blockers, angiotensin-
onverting enzyme inhibitors, or clopidogrel were not
harged to the hospital, because of negotiation mechanisms
etween pharmaceutical firms and hospital pharmacy de-
artments. Physician fees are absent from our estimate, and
hysician labor costs were included only on the basis of the
umber of hours worked per patient (as patients were
reated in public non-profit facilities). This also leads to an
nderestimation of our real costs, and it partially explains a
umber of discrepancies with some studies where physician
ees ranged from $1,298 (13) to $3,372 (17,18) per patient.
he costs of medical or surgical supplies such as stents or
he cost of thrombolytic agents greatly vary from one system
o another. Some cost inputs such as maintenance, techni-
ian labor, or house-keeping inputs may have been missed
r underestimated in our micro-costing analysis. Hence, for
he purpose of checking if our results can be extrapolated, a
ensitivity analysis was performed whereby U.S. and U.K.
osts (based on charges reduced to costs) were applied to our
atients. Total costs measured were, at the end of the first
n-hospital period, respectively 1.9 and 1.6 times higher
han using our local costs. This estimate using U.S. costs
as slightly higher than the costs assessed in Stent-PAMI,
his being the result of a longer hospital stay after AMI in
ur study than in the U.S. Every cost component (hospi-
alization, revascularization procedures, pharmacy) was 1.6
o 2.3 times higher in the U.S., except for pre-hospital care
because of the particular organization of our mobile care
nit allowing PHT with a physician on board the ambu-
ance). The cost difference between the two strategies in
avor of PCA remains unchanged, PCA being 7.5% to 11%
ess expensive than PHT regardless of the health care and
ccounting system chosen.
Another parameter largely varying from one country to
nother is the rate of revascularization during the in-
ospital period. It was 62% for our PHT group (including
5% of rescue angioplasty). In comparison with other
tudies, this rate is high, ranging from 42% (13) to 60%
18,25) in most of them, but is as low as 15% and 17% in
ome countries (25) or studies (8) where rescue angioplasty
fter thrombolysis was rarely performed. From our subgroup
nalysis, PHT patients with no rescue or emergent PCA
emained 4% non-significantly costlier than PCA patients,
hereas PHT patients with PCI were 15% higher in cost.
onsequently, the revascularization rate only mildly influ-
nces the costs difference between the two strategies. Ad-
usting for other different variables did not significantly alter
he cost difference in favor of the PCA arm. However, the
ower cost of PCA over PHT was large for low-risk AMI
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February 15, 2005:515–24 The CAPTIM Cost-Efficacy Sub-Studyatients at presentation for those who did not require a
TCA after the initial coronary angiography and for event-
ree patients during the in-hospital period. For high-risk
atients at presentation, there was no cost difference be-
ween the two strategies, but for this subset of patients PHT
as advantages in terms of efficacy: cardiogenic shock
ccurred less often, and mortality had a trend to be lower for
MI patients treated early (20).
Interestingly, the total hospital cost in the fibrinolytic
roup of the CAPTIM study was comparable or even lower
n constant currency terms than the cost of myocardial
nfarction patients treated with alteplase in the 1990s in the
ame institutions, before the era of primary or rescue
ngioplasty (26). In this earlier study, the mortality rate and
he hospital stay were far higher.
tudy limitations. This prospective sub-study was per-
ormed only on a subset of 299 patients from the 840
nrolled in the CAPTIM trial in the three university
ospitals that initiated the main trial. Baseline data are well
alanced between the whole group of patients and the
ub-study patients, as the randomization of patients was
tratified in each center. These three institutions are within
00 miles of each other, permitting the efficient and
ccurate collection of all the resources used by the two
ellows and the research nurse. The micro-costing evalua-
ion was performed in two of the three hospitals and then
xtrapolated to the third. These three structures have similar
linical standards and the same financial and accounting
ystem. Extrapolation to other health care systems may be
uestioned as details of costing differ from one country to
nother. Clinical decisions are conducted through the same
uidelines; however, the rate of catheterization after throm-
olysis can differ from one country to another. Nevertheless,
ur sensitivity analyses show that the results would not have
een drastically different.
This study is, to our knowledge, the first comparing
CA with PHT and liberal use of rescue angioplasty.
owever, the comparison between primary angioplasty
nd PHT followed by systematic 60- to 90-min coronary
ngiography and angioplasty if necessary (“facilitated
ngioplasty”) also needs to be explored in terms of efficacy
nd costs.
Our results suggest that PHT and PCA are as effective
or AMI patients close to an available PCI center, PHT
eing probably more effective than PCA for very early
resenters (2 h). These conclusions cannot be extrapolated
o other AMI patients, especially when the patient cannot
e transported within 1 h to a PCI center.
uture directions. In the light of our results and the other
ecent studies, patients more than 60 min from the cathe-
erization laboratory and those early presenters within 2 to
h from onset of symptoms should benefit from PHT.
onversely, patients presenting later and within 1 h of the
CI center should be referred directly to the catheterization
aboratory without performing PHT. Importantly, we will
einforce the pre-hospital triage of every AMI patient viahe mobile care unit to optimize the network of care for
hese patients. Some questions remain open to discussion in
he following setting: Should immediate transfer to a PCI
enter be applied to all AMI patients after PHT, or should
t be reserved only for high-risk patients with failed reper-
usion or in hemodynamically unstable condition? Because
0% to 15% of our patients treated with PTCA were
ospitalized for a second procedure, will “active” stents
urther reduce the re-hospitalization rate by reducing the
estenosis rate? Ongoing studies should provide answers to
hese important points.
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